Business Context and Reporting Period
This Form 8-K is a current report filed by Lion Biotechnologies, Inc. on October 3, 2016. The filing discloses the appointment of a new Chief Financial Officer (CFO) and details the associated compensatory arrangements. Note: The request metadata references "IOVANCE BIOTHERAPEUTICS, INC.", but the filing text explicitly identifies the registrant as Lion Biotechnologies, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Sign-on Bonus: $40,000
- Annual Base Salary: $450,000
- Stock Options: Grant of 300,000 shares (exercise price to be set at fair market value on grant date).
- Annual Incentive Target: 40% of base salary (contingent on performance objectives).
- Severance (Termination without cause): Six months of base salary plus prorated incentive compensation.
Material Changes
The primary material change is the appointment of Gregory T. Schiffman as Chief Financial Officer, effective October 3, 2016. This replaces the previous CFO structure and introduces new equity and cash compensation obligations for the company.
Outlook, Risks, and Unusual Items
Management Commentary: The filing outlines Mr. Schiffman's extensive background in biotechnology finance, including prior roles as CFO at StemCells, Inc., Dendreon Corporation, and Affymetrix.
Compensation Structure:
- Vesting Schedule: 100,000 options vest on the one-year anniversary; the remaining 200,000 options vest quarterly (25,000 shares per quarter) over the subsequent two years.
- Acceleration: Upon termination without cause, all unvested stock options become fully vested, exercisable within six months.
- Employment Status: Employment is "at-will" with no specific term.
Risks/Contingencies: The company faces future cash outflows for salary, bonuses, and potential severance. The incentive plan is contingent on the satisfaction of individual and company objectives established by the Board.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 300,000 stock options at the next Board meeting.
- Confirm the specific performance metrics established for the annual incentive compensation plan.
- Review the impact of the new CFO's compensation on the company's cash burn rate and dilution.
- Check for any concurrent departure of the previous CFO not detailed in this specific item.